Pulmonary Disease, Chronic Obstructive
Conditions
Keywords
Severe and very severe COPD (GOLD stage III / IV) exacerbations, health care utilisation, Chronic Obstructive Pulmonary Disease (COPD), quality of life, compliance, salmeterol/fluticasone combination
Brief summary
This is a 12 month randomized, open-label, parallel-group study to obtain data on the frequency and variability of exacerbations in severe and very severe Chronic Obstructive Pulmonary Disease (COPD) patients (Global Initiative for Chronic Obstructive Lung Disease (GOLD) Stage III and IV) receiving salmeterol xinafoate and fluticasone propionate either in fixed combination (SFC) or from separate inhalers (Sal/FP) with standard therapy. 200 subjects will be enrolled in approximately 30 study centres in Germany. Data on health care utilisation will be collected to compare direct costs associated with COPD in these two groups. Baseline data will be collected for all subjects at Visit 1 and eligible subjects will be randomized to receive either SFC 50/500 µg bid (twice daily) as fixed combination or Sal 50 µg bid (twice daily) and FP 500 µg bid (twice daily) concurrently over 52 weeks. Subjects will return for study visits every two to three months until week 52. Additional telephone calls will be made between scheduled visits every 4 weeks. Assessments will include monitoring of frequency of exacerbations, health care utilisation (including emergency visits and hospitalizations) and rescue medication, lung function, drug compliance, health-related quality of life (SGRQ = St George's Respiratory Questionnaire) and safety.
Detailed description
A 12 month open-label randomized parallel group study to investigate the influence of salmeterol xinafoate/fluticasone propionate either in fixed combination (SFC50/500 µg bid) or separately (SAL 50 µg and FP 500 µg bid) via Diskus inhalers on the course of the disease and frequency of exacerbations in subjects with severe and very severe COPD ( GOLD stage III+IV)
Interventions
DRUGSalmeterol / Fluticasone (50/500 µg) BID fixed combination
comparator
DRUGSalmeterol / Fluticasone (50/500 µg) BID separate Inhalers
comparator
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subject must have a diagnosis of COPD based on the American Thoracic Society (ATS)/ European Respiratory Society (ERS) criteria. * Male or female subjects, aged \>=40 years. Females must be of Non Child Bearing Potential. The definition of Non Child Bearing Potential is as following: Females, regardless of their age, with functioning ovaries and who have a current documented tubal ligation or hysterectomy, or females who are post-menopausal. * Have diagnosed COPD stage III or IV according to GOLD criteria: a baseline post-bronchodilator Forced Expiratory Volume, measured at 1 second (FEV1) \<50% of predicted normal and a baseline post- bronchodilator FEV1/Inspiratory Vital Capacity (IVC) ratio \<70%. * Have experienced at least 2 moderate or severe COPD exacerbations leading to medical consultation (requiring oral corticosteroids or increasing dosage of oral corticosteroids and/or antibiotics or hospitalization) within the 12 months preceding Visit 1. * Have stable COPD medication within 4 weeks prior to Visit 1 (no new medication added and no dosage changes in medication). * Current or ex-smokers with a smoking history of at least 10 pack years (number of pack years = \[number of cigarettes per day / 20\] x number of years smoked, e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years). * Are currently managed at home (outpatients), are ambulatory and able to travel to the clinic. Subjects can be treated with all relevant COPD medication. This includes vaccines, inhaled short-acting beta-2-agonists as needed, short-acting or long-acting anticholinergics (tiotropium), systemic beta-2-agonists, theophylline, mucolytics, antioxidants, beta-1-agonists (for cardiovascular indication), non-invasive ventilation, long term oxygen therapy and can have Cor Pulmonale. * A signed and dated written informed consent is obtained prior to participation. * Able to comply with the requirements of the protocol and be available for study visits over 52 weeks.
Exclusion criteria
* Known other respiratory disorders or signs for other respiratory disorders (e.g. asthma, lung cancer, sarcoidosis, tuberculosis, lung fibrosis, cystic fibrosis, bronchoectasis). * Known history of significant inflammatory disease, other than COPD (e.g. rheumatoid arthritis and systemic lupus erythematosus). * Known to be severely alpha-1-antitrypsin deficient (PI SZ or ZZ) * Having undergone lung surgery (e.g. lung resection including lung volume reduction surgery, lung transplant) or subjects scheduled for surgery. * Concurrent medication from Visit 1 and for the duration of the study with any of the prohibited medications: monoamine oxidase inhibitors and tricyclic antidepressants, and ritonavir (a highly potent cytochrome P450 3A4 inhibitor). * Subjects receiving chronic or prophylactic antibiotic therapy. * Serious, uncontrolled disease (including serious psychological disorders) likely to interfere with the study or impact on subject safety. * Have, in the opinion of the investigator, evidence of alcohol, drug or solvent abuse. * History of depression. * History or presence of clinically significant drug sensitivity or clinically significant allergic reaction to corticosteroids or salmeterol. * Moderate or severe COPD exacerbation (requiring corticosteroids or increased dosage of corticosteroids and/or antibiotics or hospitalization) within the 4 weeks prior to Visit 1 * Lower respiratory tract infection within the 4 weeks prior to Visit 1 . * Pregnant or lactating female and female of childbearing potential. * Subject is a participating investigator, sub-investigator, study coordinator, or other employee of a participating investigator, or is an immediate family member of the before mentioned. Subject is an employee of GlaxoSmithKline (GSK). * Subject participated in an investigational drug study within 30 days prior to Visit 1
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Number of Exacerbations Per Year: Negative Binomial Model | Baseline through Week 52 | During regular visits, participants were asked whether they experienced any exacerbation since last contact. Between visits, COPD participants were contacted by phone by the staff and asked about exacerbation details. Exacerbations were defined according to Rodriguez-Roisin: moderate (grade II) exacerbations include a worsening of COPD symptoms that require both a change of respiratory medication (increased dose of prescribed or addition of new drugs) and medical assistance; severe (grade III) exacerbations include deterioration in COPD resulting in hospitalization or emergency room treatment. |
| Mean Number of Exacerbations Per Year: Poisson Model | Baseline through Week 52 | During regular visits, participants were asked whether they experienced any exacerbation since last contact. Between visits, COPD participants were contacted by phone by the staff and asked about exacerbation details. Exacerbations were defined according to Rodriguez-Roisin: moderate (grade II) exacerbations include a worsening of COPD symptoms that require both a change of respiratory medication (increased dose of prescribed or addition of new drugs) and medical assistance; severe (grade III) exacerbations include deterioration in COPD resulting in hospitalization or emergency room treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With the Indicated Number of Days at the Intensive Care Unit (ICU) | Baseline through Week 52 | The number participants with the indicated number of days at the ICU was recorded. |
| Number of Participants With the Indicated Number of Hospital Stays | Baseline through Week 52 | The number of participants with the indicated number of hospitalizations was recorded. |
| Mean Number of Days Rescue Medication Was Used | The 7 days before baseline (=Visit 2 [Week 8]) and the last 7 days of study (=Visit 6 [Week 52]) | Participants were asked for the number of days they used rescue medication within the 7 days before Week 8 and Week 52. |
| Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 52 | Baseline and Week 52 | Change from baseline was calculated as the FEV1 percent predicted value at Week 52 minus the percent predicted value at baseline. The post-bronchodilator lung function test was performed to measure FEV1 30 minutes after inhaling salbutamol. The most reliable result of three different consecutive measurements was documented. |
| Mean Change From Baseline in Inspiratory Vital Capacity (IVC) at Week 52 | Baseline and Week 52 | Change from baseline was measured as the IVC value at Week 52 minus the value at baseline. The post-bronchodilator lung function test was performed to measure IVC 30 minutes after inhaling salbutamol. The most reliable result of three different, consecutive measurements was documented. |
| Compliance and Adherence to Study Medication | Baseline through Week 52 | Compliance is calculated as the ratio (in percent) between the number of actual doses taken during the total treatment period divided by the number of doses that should have been taken during the total treatment period. |
| Mean Change From Baseline in the Symptom Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Baseline and Week 52 | Change from baseline is calculated as the symptom score at Week 52 minus the symptom score at baseline. The SGRQ (a self-administered questionnaire) subscale symptom score ranges from 0 to 100% and measures the effect of respiratory symptoms, frequency, and severity on quality of life (summed weights of 8 questions). A score of 0 indicates the best possible status. |
| Mean Change From Baseline in the Activity Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Baseline and Week 52 | Change from baseline is calculated as the activity score at Week 52 minus the score at baseline. The SGRQ (a self-administered questionnaire) subscale activity score ranges from 0 to 100% and is concerned with activities that cause or are limited by breathlessness (summed weights of 2 questions). A score of 0 indicates the best possible status. |
| Mean Change From Baseline in the Impact Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Baseline and Week 52 | Change from baseline was calculated as the impact score at Week 52 minus the score at baseline. The SGRQ (a self-administered questionnaire) subscale impact score ranges from 0 to 100% and is concerned with social functioning and psychological disturbances (summed weights of 5 questions). A score of 0 indicates the best possible status. |
| Mean Change From Baseline in the Total Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Baseline and Week 52 | Change from baseline was calculated as the total score at Week 52 minus the score at baseline. The SGRQ (a self-administered questionnaire) total score ranges from 0 to 100% and summarizes the impact of COPD on overall health status (summed weights of 15 questions). A total score of 0 indicates the best possible status. |
| Mean Total Costs (Related to COPD) Per Participant | Baseline through Week 52 | Total costs include costs for hospitalization, medication, and visits to/by physician. Medications that were used as required were assumed to be used every second day. |
| Mean Change From Baseline in the Tiffeaneau Index at Week 52 | Baseline and Week 52 | The Tiffeneau index is defined as the FEV1 divided by the IVC (i.e., forced expiratory volume in one second relative to the inspiratory capacity) in percent. Change from baseline is calculated as the FEV1/IVC value at Week 52 minus the value at baseline. |
| Mean Number of COPD-related Visits at/by Physician | Baseline through Week 52 | The total number of COPD-related visits, i.e., from baseline through week 52, the number of visits at physician's office, the number of home visits made by physician, the number of visits at an emergency outpatient clinic, as well as the number of home visits by an emergency physician were summed up. |
Countries
Germany
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg Salmeterol xinafoate/fluticasone propionate (FP) 50/500 µg twice a day (BID) (morning and evening) from the fixed combination inhaler (VIANI forte Diskus) | 107 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg Salmeterol xinafoate (Sal)/fluticasone propionate (FP) 50/500 µg BID (morning and evening) from two separate inhalers (SEREVENT Diskus and FLUTIDE forte Diskus) | 105 |
| Total | 212 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Additional Intake of Viani forte | 0 | 1 |
| Overall Study | Adverse Event | 10 | 10 |
| Overall Study | Alpha-1 Antitrypsin Deficiency | 0 | 1 |
| Overall Study | Inclusion Criteria Not Met | 3 | 3 |
| Overall Study | Lost to Follow-up | 3 | 2 |
| Overall Study | Participant moved away | 0 | 1 |
| Overall Study | Withdrawal by Subject | 5 | 8 |
Baseline characteristics
| Characteristic | Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Total |
|---|---|---|---|
| Age Continuous | 65.6 years STANDARD_DEVIATION 8.3 | 64.2 years STANDARD_DEVIATION 8.9 | 64.9 years STANDARD_DEVIATION 8.6 |
| Severity of Chronic Obstructive Lung Disease (COPD) Severe COPD | 77 participants | 79 participants | 156 participants |
| Severity of Chronic Obstructive Lung Disease (COPD) Very severe COPD | 30 participants | 26 participants | 56 participants |
| Sex: Female, Male Female | 33 Participants | 29 Participants | 62 Participants |
| Sex: Female, Male Male | 74 Participants | 76 Participants | 150 Participants |
| Smoking History Ex-smoker | 74 participants | 78 participants | 152 participants |
| Smoking History Smoker | 33 participants | 27 participants | 60 participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 45 / 108 | 48 / 105 |
| serious Total, serious adverse events | 23 / 108 | 16 / 105 |
Outcome results
Primary
Mean Number of Exacerbations Per Year: Negative Binomial Model
During regular visits, participants were asked whether they experienced any exacerbation since last contact. Between visits, COPD participants were contacted by phone by the staff and asked about exacerbation details. Exacerbations were defined according to Rodriguez-Roisin: moderate (grade II) exacerbations include a worsening of COPD symptoms that require both a change of respiratory medication (increased dose of prescribed or addition of new drugs) and medical assistance; severe (grade III) exacerbations include deterioration in COPD resulting in hospitalization or emergency room treatment.
Time frame: Baseline through Week 52
Population: Intent-to-Treat (ITT) Population: all participants receiving at least one dose of study medication and suffering from COPD
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Number of Exacerbations Per Year: Negative Binomial Model | 0.864 Number of exacerbations per year | Standard Error 0.134 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Number of Exacerbations Per Year: Negative Binomial Model | 0.862 Number of exacerbations per year | Standard Error 0.138 |
p-value: 0.73Negative binomial model
Primary
Mean Number of Exacerbations Per Year: Poisson Model
During regular visits, participants were asked whether they experienced any exacerbation since last contact. Between visits, COPD participants were contacted by phone by the staff and asked about exacerbation details. Exacerbations were defined according to Rodriguez-Roisin: moderate (grade II) exacerbations include a worsening of COPD symptoms that require both a change of respiratory medication (increased dose of prescribed or addition of new drugs) and medical assistance; severe (grade III) exacerbations include deterioration in COPD resulting in hospitalization or emergency room treatment.
Time frame: Baseline through Week 52
Population: ITT Population
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Number of Exacerbations Per Year: Poisson Model | 0.863 Number of exacerbations per year | Standard Error 0.136 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Number of Exacerbations Per Year: Poisson Model | 0.830 Number of exacerbations per year | Standard Error 0.137 |
p-value: 0.66Poisson model
Secondary
Compliance and Adherence to Study Medication
Compliance is calculated as the ratio (in percent) between the number of actual doses taken during the total treatment period divided by the number of doses that should have been taken during the total treatment period.
Time frame: Baseline through Week 52
Population: ITT Population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Compliance and Adherence to Study Medication | 97.08 percentage of doses | Standard Deviation 11.61 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Compliance and Adherence to Study Medication | 98.44 percentage of doses | Standard Deviation 19.62 |
| FP 500 µg | Compliance and Adherence to Study Medication | 98.33 percentage of doses | Standard Deviation 19.36 |
Secondary
Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 52
Change from baseline was calculated as the FEV1 percent predicted value at Week 52 minus the percent predicted value at baseline. The post-bronchodilator lung function test was performed to measure FEV1 30 minutes after inhaling salbutamol. The most reliable result of three different consecutive measurements was documented.
Time frame: Baseline and Week 52
Population: ITT Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 52 | Week 52 | 38.98 percent of predicted value | Standard Deviation 13.15 |
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 52 | Baseline | 36.82 percent of predicted value | Standard Deviation 8.93 |
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 52 | Mean change from baseline | 2.17 percent of predicted value | Standard Deviation 10.42 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 52 | Week 52 | 41.22 percent of predicted value | Standard Deviation 15.26 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 52 | Baseline | 38.15 percent of predicted value | Standard Deviation 9.26 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 52 | Mean change from baseline | 3.08 percent of predicted value | Standard Deviation 12.08 |
| FP 500 µg | Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 52 | Baseline | 37.47 percent of predicted value | Standard Deviation 9.1 |
| FP 500 µg | Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 52 | Mean change from baseline | 2.62 percent of predicted value | Standard Deviation 11.26 |
| FP 500 µg | Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 52 | Week 52 | 40.09 percent of predicted value | Standard Deviation 14.24 |
Secondary
Mean Change From Baseline in Inspiratory Vital Capacity (IVC) at Week 52
Change from baseline was measured as the IVC value at Week 52 minus the value at baseline. The post-bronchodilator lung function test was performed to measure IVC 30 minutes after inhaling salbutamol. The most reliable result of three different, consecutive measurements was documented.
Time frame: Baseline and Week 52
Population: ITT Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Change From Baseline in Inspiratory Vital Capacity (IVC) at Week 52 | Week 52 | 2.14 liters | Standard Deviation 0.72 |
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Change From Baseline in Inspiratory Vital Capacity (IVC) at Week 52 | Baseline | 2.17 liters | Standard Deviation 0.74 |
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Change From Baseline in Inspiratory Vital Capacity (IVC) at Week 52 | Mean change from baseline | -0.02 liters | Standard Deviation 0.53 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Change From Baseline in Inspiratory Vital Capacity (IVC) at Week 52 | Week 52 | 2.27 liters | Standard Deviation 0.68 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Change From Baseline in Inspiratory Vital Capacity (IVC) at Week 52 | Baseline | 2.29 liters | Standard Deviation 0.71 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Change From Baseline in Inspiratory Vital Capacity (IVC) at Week 52 | Mean change from baseline | -0.02 liters | Standard Deviation 0.5 |
| FP 500 µg | Mean Change From Baseline in Inspiratory Vital Capacity (IVC) at Week 52 | Baseline | 2.23 liters | Standard Deviation 0.72 |
| FP 500 µg | Mean Change From Baseline in Inspiratory Vital Capacity (IVC) at Week 52 | Mean change from baseline | -0.02 liters | Standard Deviation 0.51 |
| FP 500 µg | Mean Change From Baseline in Inspiratory Vital Capacity (IVC) at Week 52 | Week 52 | 2.21 liters | Standard Deviation 0.7 |
Secondary
Mean Change From Baseline in the Activity Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52
Change from baseline is calculated as the activity score at Week 52 minus the score at baseline. The SGRQ (a self-administered questionnaire) subscale activity score ranges from 0 to 100% and is concerned with activities that cause or are limited by breathlessness (summed weights of 2 questions). A score of 0 indicates the best possible status.
Time frame: Baseline and Week 52
Population: ITT Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Change From Baseline in the Activity Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Week 52 | 71.17 percent | Standard Deviation 20.29 |
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Change From Baseline in the Activity Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Baseline | 72.80 percent | Standard Deviation 17.78 |
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Change From Baseline in the Activity Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Mean change from baseline | -1.63 percent | Standard Deviation 16.63 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Change From Baseline in the Activity Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Week 52 | 68.53 percent | Standard Deviation 21.72 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Change From Baseline in the Activity Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Baseline | 70.64 percent | Standard Deviation 17.45 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Change From Baseline in the Activity Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Mean change from baseline | -2.11 percent | Standard Deviation 16.53 |
| FP 500 µg | Mean Change From Baseline in the Activity Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Baseline | 71.73 percent | Standard Deviation 17.61 |
| FP 500 µg | Mean Change From Baseline in the Activity Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Mean change from baseline | -1.87 percent | Standard Deviation 16.54 |
| FP 500 µg | Mean Change From Baseline in the Activity Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Week 52 | 69.86 percent | Standard Deviation 21.01 |
Secondary
Mean Change From Baseline in the Impact Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52
Change from baseline was calculated as the impact score at Week 52 minus the score at baseline. The SGRQ (a self-administered questionnaire) subscale impact score ranges from 0 to 100% and is concerned with social functioning and psychological disturbances (summed weights of 5 questions). A score of 0 indicates the best possible status.
Time frame: Baseline and Week 52
Population: ITT Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Change From Baseline in the Impact Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Week 52 | 44.66 percent | Standard Deviation 21.15 |
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Change From Baseline in the Impact Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Baseline | 46.03 percent | Standard Deviation 20.3 |
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Change From Baseline in the Impact Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Mean change from baseline | -1.37 percent | Standard Deviation 17.52 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Change From Baseline in the Impact Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Week 52 | 41.26 percent | Standard Deviation 19.53 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Change From Baseline in the Impact Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Baseline | 43.58 percent | Standard Deviation 17.37 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Change From Baseline in the Impact Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Mean change from baseline | -2.32 percent | Standard Deviation 17.87 |
| FP 500 µg | Mean Change From Baseline in the Impact Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Baseline | 44.82 percent | Standard Deviation 18.9 |
| FP 500 µg | Mean Change From Baseline in the Impact Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Mean change from baseline | -1.84 percent | Standard Deviation 17.66 |
| FP 500 µg | Mean Change From Baseline in the Impact Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Week 52 | 42.98 percent | Standard Deviation 20.39 |
Secondary
Mean Change From Baseline in the Symptom Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52
Change from baseline is calculated as the symptom score at Week 52 minus the symptom score at baseline. The SGRQ (a self-administered questionnaire) subscale symptom score ranges from 0 to 100% and measures the effect of respiratory symptoms, frequency, and severity on quality of life (summed weights of 8 questions). A score of 0 indicates the best possible status.
Time frame: Baseline and Week 52
Population: ITT Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Change From Baseline in the Symptom Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Week 52 | 65.42 percent | Standard Deviation 19.76 |
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Change From Baseline in the Symptom Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Baseline | 68.80 percent | Standard Deviation 19.65 |
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Change From Baseline in the Symptom Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Mean change from baseline | -3.38 percent | Standard Deviation 17.65 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Change From Baseline in the Symptom Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Week 52 | 63.77 percent | Standard Deviation 19.94 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Change From Baseline in the Symptom Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Baseline | 68.95 percent | Standard Deviation 18.38 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Change From Baseline in the Symptom Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Mean change from baseline | -5.18 percent | Standard Deviation 17.27 |
| FP 500 µg | Mean Change From Baseline in the Symptom Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Baseline | 68.88 percent | Standard Deviation 18.99 |
| FP 500 µg | Mean Change From Baseline in the Symptom Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Mean change from baseline | -4.27 percent | Standard Deviation 17.44 |
| FP 500 µg | Mean Change From Baseline in the Symptom Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Week 52 | 64.61 percent | Standard Deviation 19.82 |
Secondary
Mean Change From Baseline in the Tiffeaneau Index at Week 52
The Tiffeneau index is defined as the FEV1 divided by the IVC (i.e., forced expiratory volume in one second relative to the inspiratory capacity) in percent. Change from baseline is calculated as the FEV1/IVC value at Week 52 minus the value at baseline.
Time frame: Baseline and Week 52
Population: ITT Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Change From Baseline in the Tiffeaneau Index at Week 52 | Week 52 | 50.82 percent of IVC | Standard Deviation 10.98 |
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Change From Baseline in the Tiffeaneau Index at Week 52 | Baseline | 48.90 percent of IVC | Standard Deviation 11.09 |
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Change From Baseline in the Tiffeaneau Index at Week 52 | Mean change from baseline | 1.92 percent of IVC | Standard Deviation 8.76 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Change From Baseline in the Tiffeaneau Index at Week 52 | Week 52 | 52.83 percent of IVC | Standard Deviation 16.39 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Change From Baseline in the Tiffeaneau Index at Week 52 | Baseline | 49.05 percent of IVC | Standard Deviation 10.76 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Change From Baseline in the Tiffeaneau Index at Week 52 | Mean change from baseline | 3.78 percent of IVC | Standard Deviation 13.42 |
| FP 500 µg | Mean Change From Baseline in the Tiffeaneau Index at Week 52 | Baseline | 48.98 percent of IVC | Standard Deviation 10.9 |
| FP 500 µg | Mean Change From Baseline in the Tiffeaneau Index at Week 52 | Mean change from baseline | 2.84 percent of IVC | Standard Deviation 11.32 |
| FP 500 µg | Mean Change From Baseline in the Tiffeaneau Index at Week 52 | Week 52 | 51.81 percent of IVC | Standard Deviation 13.93 |
Secondary
Mean Change From Baseline in the Total Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52
Change from baseline was calculated as the total score at Week 52 minus the score at baseline. The SGRQ (a self-administered questionnaire) total score ranges from 0 to 100% and summarizes the impact of COPD on overall health status (summed weights of 15 questions). A total score of 0 indicates the best possible status.
Time frame: Baseline and Week 52
Population: ITT Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Change From Baseline in the Total Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Week 52 | 56.02 percent | Standard Deviation 18.22 |
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Change From Baseline in the Total Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Baseline | 57.82 percent | Standard Deviation 17.07 |
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Change From Baseline in the Total Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Mean change from baseline | -1.80 percent | Standard Deviation 14.42 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Change From Baseline in the Total Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Week 52 | 53.25 percent | Standard Deviation 17.71 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Change From Baseline in the Total Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Baseline | 55.89 percent | Standard Deviation 15.36 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Change From Baseline in the Total Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Mean change from baseline | -2.64 percent | Standard Deviation 14.73 |
| FP 500 µg | Mean Change From Baseline in the Total Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Baseline | 56.87 percent | Standard Deviation 16.24 |
| FP 500 µg | Mean Change From Baseline in the Total Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Mean change from baseline | -2.22 percent | Standard Deviation 14.55 |
| FP 500 µg | Mean Change From Baseline in the Total Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Week 52 | 54.65 percent | Standard Deviation 17.98 |
Secondary
Mean Number of COPD-related Visits at/by Physician
The total number of COPD-related visits, i.e., from baseline through week 52, the number of visits at physician's office, the number of home visits made by physician, the number of visits at an emergency outpatient clinic, as well as the number of home visits by an emergency physician were summed up.
Time frame: Baseline through Week 52
Population: ITT Population with non-missing data (due to early withdrawal some data for this outcome measure are missing)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Number of COPD-related Visits at/by Physician | 1.39 number of visits | Standard Deviation 2.33 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Number of COPD-related Visits at/by Physician | 1.06 number of visits | Standard Deviation 2.23 |
| FP 500 µg | Mean Number of COPD-related Visits at/by Physician | 1.23 number of visits | Standard Deviation 2.28 |
Secondary
Mean Number of Days Rescue Medication Was Used
Participants were asked for the number of days they used rescue medication within the 7 days before Week 8 and Week 52.
Time frame: The 7 days before baseline (=Visit 2 [Week 8]) and the last 7 days of study (=Visit 6 [Week 52])
Population: ITT Population with non-missing data (due to early withdrawal, some data for this outcome measure are missing).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Number of Days Rescue Medication Was Used | Final visit (Week 52) | 5.03 number of days | Standard Deviation 2.45 |
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Number of Days Rescue Medication Was Used | Visit 2 (Week 8) | 4.73 number of days | Standard Deviation 2.37 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Number of Days Rescue Medication Was Used | Visit 2 (Week 8) | 4.11 number of days | Standard Deviation 2.77 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Number of Days Rescue Medication Was Used | Final visit (Week 52) | 4.69 number of days | Standard Deviation 2.67 |
| FP 500 µg | Mean Number of Days Rescue Medication Was Used | Visit 2 (Week 8) | 4.43 number of days | Standard Deviation 2.58 |
| FP 500 µg | Mean Number of Days Rescue Medication Was Used | Final visit (Week 52) | 4.86 number of days | Standard Deviation 2.56 |
Secondary
Mean Total Costs (Related to COPD) Per Participant
Total costs include costs for hospitalization, medication, and visits to/by physician. Medications that were used as required were assumed to be used every second day.
Time frame: Baseline through Week 52
Population: ITT Population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Mean Total Costs (Related to COPD) Per Participant | 1453 Euros per participant | Standard Deviation 2427 |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Mean Total Costs (Related to COPD) Per Participant | 1166 Euros per participant | Standard Deviation 1534 |
| FP 500 µg | Mean Total Costs (Related to COPD) Per Participant | 1311 Euros per participant | Standard Deviation 2034 |
Secondary
Number of Participants With the Indicated Number of Days at the Intensive Care Unit (ICU)
The number participants with the indicated number of days at the ICU was recorded.
Time frame: Baseline through Week 52
Population: ITT Population of participants who were admitted to the ICU
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Number of Participants With the Indicated Number of Days at the Intensive Care Unit (ICU) | 11-30 days | 0 participants |
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Number of Participants With the Indicated Number of Days at the Intensive Care Unit (ICU) | 6-10 days | 1 participants |
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Number of Participants With the Indicated Number of Days at the Intensive Care Unit (ICU) | 0 days | 19 participants |
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Number of Participants With the Indicated Number of Days at the Intensive Care Unit (ICU) | 1-5 days | 4 participants |
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Number of Participants With the Indicated Number of Days at the Intensive Care Unit (ICU) | >30 days | 1 participants |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Number of Participants With the Indicated Number of Days at the Intensive Care Unit (ICU) | 6-10 days | 1 participants |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Number of Participants With the Indicated Number of Days at the Intensive Care Unit (ICU) | 0 days | 13 participants |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Number of Participants With the Indicated Number of Days at the Intensive Care Unit (ICU) | 1-5 days | 2 participants |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Number of Participants With the Indicated Number of Days at the Intensive Care Unit (ICU) | 11-30 days | 0 participants |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Number of Participants With the Indicated Number of Days at the Intensive Care Unit (ICU) | >30 days | 0 participants |
| FP 500 µg | Number of Participants With the Indicated Number of Days at the Intensive Care Unit (ICU) | >30 days | 1 participants |
| FP 500 µg | Number of Participants With the Indicated Number of Days at the Intensive Care Unit (ICU) | 11-30 days | 0 participants |
| FP 500 µg | Number of Participants With the Indicated Number of Days at the Intensive Care Unit (ICU) | 0 days | 32 participants |
| FP 500 µg | Number of Participants With the Indicated Number of Days at the Intensive Care Unit (ICU) | 6-10 days | 2 participants |
| FP 500 µg | Number of Participants With the Indicated Number of Days at the Intensive Care Unit (ICU) | 1-5 days | 6 participants |
Secondary
Number of Participants With the Indicated Number of Hospital Stays
The number of participants with the indicated number of hospitalizations was recorded.
Time frame: Baseline through Week 52
Population: ITT Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Number of Participants With the Indicated Number of Hospital Stays | 0 hospital stays | 82 participants |
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Number of Participants With the Indicated Number of Hospital Stays | 1 hospital stay | 11 participants |
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Number of Participants With the Indicated Number of Hospital Stays | 2 hospital stays | 9 participants |
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Number of Participants With the Indicated Number of Hospital Stays | 3 hospital stays | 4 participants |
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Number of Participants With the Indicated Number of Hospital Stays | 4 hospital stays | 0 participants |
| Salmeterol Xinafoate/FP in Fixed Combination (SFC) 50/500 µg | Number of Participants With the Indicated Number of Hospital Stays | 5 or more hospital stays | 1 participants |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Number of Participants With the Indicated Number of Hospital Stays | 5 or more hospital stays | 0 participants |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Number of Participants With the Indicated Number of Hospital Stays | 0 hospital stays | 87 participants |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Number of Participants With the Indicated Number of Hospital Stays | 3 hospital stays | 1 participants |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Number of Participants With the Indicated Number of Hospital Stays | 4 hospital stays | 1 participants |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Number of Participants With the Indicated Number of Hospital Stays | 1 hospital stay | 13 participants |
| Salmeterol Xinafoate/FP Separately (Sal/FP) 50/500 µg | Number of Participants With the Indicated Number of Hospital Stays | 2 hospital stays | 3 participants |
| FP 500 µg | Number of Participants With the Indicated Number of Hospital Stays | 1 hospital stay | 24 participants |
| FP 500 µg | Number of Participants With the Indicated Number of Hospital Stays | 2 hospital stays | 12 participants |
| FP 500 µg | Number of Participants With the Indicated Number of Hospital Stays | 5 or more hospital stays | 1 participants |
| FP 500 µg | Number of Participants With the Indicated Number of Hospital Stays | 3 hospital stays | 5 participants |
| FP 500 µg | Number of Participants With the Indicated Number of Hospital Stays | 0 hospital stays | 169 participants |
| FP 500 µg | Number of Participants With the Indicated Number of Hospital Stays | 4 hospital stays | 1 participants |